CDEK
← All drugs Report issue

plerixafor

Trade name: mozobil

Small moleculeapprovedOrphan Drug FDA

Approved

Dec 15, 2008

Plerixafor is a bicyclam molecule, which has been identified as a specific antagonist of CXCR4. It had originally been developed as an inhibitor of T-tropic human immunodeficiency virus, but later demonstrated to be an effective mobilizer of hematopoietic stem cells. Plerixafor was approved by FDA for autologous transplantation (in combination with granulocyte-colony stimulating factor) in patients with non-Hodgkin's lymphoma and multiple myeloma under the name Mozobil. — NCATS

Clinical trial activity

147 trials · 106 clinical orgs · 11 marketing orgs

Phase 1
67
Phase 2
92
Phase 3
6
Phase 4
5

Earliest trial started Oct 1, 2003 (NCT00291811)

Timeline

2000s

  1. Jul 10, 2003

    Orphan Drug Designation

  2. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  4. Jan 1, 2005

    Genzyme — Earliest Phase 3 Sponsor(trial)

  5. Dec 15, 2008

    Genzyme — Earliest FDA Approval

  6. Dec 15, 2008

    Genzyme — NDA Organization

2020s

  1. Aug 10, 2020

    Dr. Reddy's Laboratories — Marketing Organization

  2. May 19, 2022

    MSN Laboratories — Marketing Organization

  3. Jul 24, 2023

    Amneal Pharmaceuticals — Marketing Organization

  4. Jul 24, 2023

    Eugia Pharma — Marketing Organization

  5. Jul 24, 2023

    KINDOS — Marketing Organization

  6. Jul 24, 2023

    Teva — Marketing Organization

  7. Jul 24, 2023

    Meitheal — Marketing Organization

  8. Jul 26, 2023

    Zydus Discovery DMCC — Marketing Organization

  9. May 3, 2024

    Gland Pharma Ltd — Marketing Organization

  10. Jun 16, 2025

    Hetero Labs Ltd — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewDec 15, 2008

Chemistry & pharmacology

Loading structure…

SMILES

C(N1CCCNCCNCCCNCC1)C2=CC=C(CN3CCCNCCNCCCNCC3)C=C2
Mol. weight
502.782 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

First in class

Sources

Also known as

  • 1,1'-(1,4-phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate
  • 1,1'-(1,4-phenylenebis(methylene))bis(1,4,8,11-tetraazacyclotetradecane)octahydrochloride dihydrate
  • amd3100
  • amd3100
  • amd3100
  • amd 3100
  • amd 3100
  • amd-3100
  • amd-3100
  • amd-3100
  • amd 3329
  • amd-3329
  • bicyclam
  • bicyclam
  • gz316455
  • jm3100
  • jm 3100
  • jm-3100
  • mezobil
  • mozobil
  • mozobil
  • mozobil
  • mozobil
  • mozobil
  • mozobil
  • perixafor
  • plerixafor
  • plerixafor
  • plerixafor
  • plerixafor
  • plerixafor
  • plerixafor
  • plerixafor
  • plerixafor
  • plerixafor
  • plerixafor
  • plerixafor
  • plerixafor
  • plerixafor hydrochloride
  • plerixafor hydrochloride
  • rpa bicyclam

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06851767Phase 1/Phase 2 (Phase 2)Mar 20, 2025National Institute of Allergy and Infectious Diseases (NIAID)
NCT06506461Phase 1Dec 31, 2024St. Jude Children's Hospital
NCT06207799Phase 2Jul 17, 2024Pfizer, University of Texas at Houston
NCT06414889Phase 1May 20, 2024University of Texas at Houston
NCT06325709Phase 1/Phase 2 (Phase 2)Apr 17, 2024National Institute of Allergy and Infectious Diseases (NIAID)
NCT06158828Phase 1/Phase 2 (Phase 2)Mar 31, 2024Rising Tide Foundation, The Leukemia and Lymphoma Society, Washington University in St. Louis
NCT06141304Phase 2Sep 1, 2023Jinlin University
NCT05343572Early Phase 1 (Phase 1)Dec 31, 2022Yale University
NCT05510544Phase 4Aug 30, 2022Peking University
NCT05411575Phase 2Jul 19, 20224Pharma Ltd.
NCT05445128Phase 2Jun 24, 2022bluebird bio, Magenta Therapeutics
NCT05357482Phase 1/Phase 2 (Phase 2)May 12, 2022National Heart, Lung, and Blood Institute (NHLBI)
NCT04817345Phase 2Jan 31, 2022Doris Duke Charitable Foundation, St. Jude Children's Hospital
NCT05087212Phase 4Oct 22, 2021Sanofi
NCT05088356Phase 1Sep 7, 2021Orca Biosystems, Inc., Stanford University
NCT05007652Phase 2Aug 31, 2021Kyowa Hakko Kirin
NCT04762875Phase 2Jun 16, 2021Magenta Therapeutics, National Marrow Donor Program
NCT04552743Phase 2Oct 5, 2020Stanford University
NCT04362293Phase 2Apr 30, 2020St. Jude Children's Hospital
NCT04177810Phase 2Feb 29, 2020American Association for Cancer Research, Genzyme, Johns Hopkins University
Showing 20 of 147 trials
Page 1 / 8

Organizations

Research & Development (106)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GenzymeFor profit442452003
SanofiFor profit13342013
National Cancer Institute (NCI)Government12142009
Washington University in St. LouisAcademic/Hospital111122004
University of WashingtonAcademic/Hospital9932009
National Heart, Lung, and Blood Institute (NHLBI)Government8432004
University of Texas at HoustonAcademic/Hospital6622009
Harvard UniversityAcademic/Hospital5522009
National Institute of Allergy and Infectious Diseases (NIAID)Government5532009
St. Jude Children's HospitalAcademic/Hospital5522010
AnorMEDFor profit4012004
Cornell UniversityAcademic/Hospital4422011
Emory UniversityAcademic/Hospital4322010
Stanford UniversityAcademic/Hospital4422014
City of Hope National Medical CenterAcademic/Hospital3322010
Duke UniversityAcademic/Hospital3322009
Magenta TherapeuticsFor profit3322019
bluebird bioFor profit2122014
Case Western Reserve UniversityAcademic/Hospital2222011
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyGovernment2212016
106 organizations
Page 1 / 6

Marketing (14)

OrganizationOrg typeRelationshipDate
Amneal PharmaceuticalsFor profitMKTGJul 24, 2023
Dr. Reddy's LaboratoriesFor profitMKTGAug 10, 2020
Dr. Reddy's LaboratoriesFor profitSYNJul 24, 2023
Eugia PharmaFor profitMKTGJul 24, 2023
GenzymeFor profitNDADec 15, 2008
Gland Pharma LtdFor profitMKTGMay 3, 2024
Gland Pharma LtdFor profitSYNMay 3, 2024
Hetero Labs LtdFor profitMKTGJun 16, 2025
KINDOSFor profitMKTGJul 24, 2023
MSN LaboratoriesFor profitMKTGMay 19, 2022
MSN LaboratoriesFor profitSYNJul 24, 2023
MeithealFor profitMKTGJul 24, 2023
TevaFor profitMKTGJul 24, 2023
Zydus Discovery DMCCFor profitMKTGJul 26, 2023